Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.

von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y.

J Bone Oncol. 2017 Nov 24;11:1-9. doi: 10.1016/j.jbo.2017.11.004. eCollection 2018 Jun.

2.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.

PMID:
29660598
3.

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M.

Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120.

PMID:
29648580
4.

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study.

von Moos R, Body JJ, Guenther O, Terpos E, Acklin YP, Finek J, Pereira J, Maniadakis N, Hechmati G, Talbot S, Sleeboom H.

J Bone Oncol. 2018 Feb 5;10:49-56. doi: 10.1016/j.jbo.2018.01.003. eCollection 2018 Mar.

5.

Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).

Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S.

Cancer. 2018 Apr 1;124(7):1449-1454. doi: 10.1002/cncr.31234. Epub 2018 Jan 9.

PMID:
29315500
6.

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder RC, Roth A, Bodoky G, Samaras P, Berger MD, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier UR, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K; Swiss Group for Clinical Cancer Research (SAKK).

Eur J Cancer. 2018 Jan;89:82-89. doi: 10.1016/j.ejca.2017.11.005. Epub 2017 Dec 11.

PMID:
29241084
7.

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.

Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group.

Ann Oncol. 2018 Mar 1;29(3):661-668. doi: 10.1093/annonc/mdx772.

PMID:
29228091
8.

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.

de Weger VA, Goel S, von Moos R, Schellens JHM, Mach N, Tan E, Anand S, Scott JW, Lassen U.

Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80. doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3.

PMID:
29101463
9.

Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.

Samaras P, Tusup M, Nguyen-Kim TDL, Seifert B, Bachmann H, von Moos R, Knuth A, Pascolo S.

Cancer Chemother Pharmacol. 2017 Nov;80(5):1005-1012. doi: 10.1007/s00280-017-3446-y. Epub 2017 Oct 4.

PMID:
28980060
10.

Absence of evidence is not evidence of absence: the case of non-inferiority.

Klingbiel D, Thürlimann B, Brauchli P, von Moos R.

Ann Oncol. 2017 Dec 1;28(12):3100-3101. doi: 10.1093/annonc/mdx498. No abstract available.

PMID:
28945840
11.

Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients.

Zweifel M, Thürlimann B, Riniker S, Weder P, von Moos R, Pagani O, Bigler M, Rothgiesser KM, Pilop C, Hawle H, Brauchli P, Tapia C, Schoenfeld W, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Endocr Connect. 2017 Oct;6(7):549-556. doi: 10.1530/EC-17-0174. Epub 2017 Aug 16.

12.

PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.

Zimmermann M, Beer J, Bodis S, von Moos R, Vlachopoulou V, Zwahlen DR, Oehler C.

Acta Oncol. 2017 Dec;56(12):1734-1740. doi: 10.1080/0284186X.2017.1325003. Epub 2017 May 30.

PMID:
28557585
13.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

14.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

15.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thürlimann B.

J Clin Oncol. 2017 Apr 10;35(11):1179-1188. doi: 10.1200/JCO.2016.70.3116. Epub 2017 Feb 13.

PMID:
28380313
16.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20.

PMID:
28317088
17.

Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries.

Body JJ, Acklin YP, Gunther O, Hechmati G, Pereira J, Maniadakis N, Terpos E, Finek J, von Moos R, Talbot S, Sleeboom H.

J Bone Oncol. 2016 Sep 12;5(4):185-193. doi: 10.1016/j.jbo.2016.07.003. eCollection 2016 Nov.

18.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622.

19.

Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain.

von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D.

Eur J Cancer. 2017 Jan;71:80-94. doi: 10.1016/j.ejca.2016.10.021. Epub 2016 Dec 14. Review.

20.

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.

Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C.

Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16.

PMID:
27983764
21.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research.

J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14.

22.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2016 Oct 10;16(1):780.

23.

Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.

Hess V, Winterhalder R, von Moos R, Widmer L, Stocker P, Jermann M, Herrmann R, Koeberle D.

Clin Colorectal Cancer. 2017 Sep;16(3):240-245. doi: 10.1016/j.clcc.2016.07.008. Epub 2016 Jul 30.

24.

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.

Mey UJM, Renner C, von Moos R.

Hematol Oncol. 2017 Dec;35(4):890-893. doi: 10.1002/hon.2353. Epub 2016 Sep 19.

PMID:
27641727
25.

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

Metaxas Y, Cathomas R, Mark M, von Moos R.

Lung Cancer. 2016 Dec;102:136-138. doi: 10.1016/j.lungcan.2016.07.012. Epub 2016 Jul 14.

PMID:
27440191
26.

Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).

Matter-Walstra K, Schwenkglenks M, Betticher D, von Moos R, Dietrich D, Baertschi D, Koeberle D.

Clin Colorectal Cancer. 2016 Dec;15(4):314-320.e2. doi: 10.1016/j.clcc.2016.03.002. Epub 2016 Mar 31.

PMID:
27117056
27.

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer.

Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez-MacGregor M, Liede A, Arellano J, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Aug;24(8):3557-65. doi: 10.1007/s00520-016-3154-x. Epub 2016 Mar 29.

28.

The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.

Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, Mihic-Probst D, von Moos R, Najafi Y, Guckenberger M, Arnold A.

Swiss Med Wkly. 2016 Feb 22;146:w14279. doi: 10.4414/smw.2016.14279. eCollection 2016. Review.

29.

Cost of skeletal complications from bone metastases in six European countries.

Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R.

J Med Econ. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016 Feb 23.

PMID:
26849381
30.

[Is prescription of a therapy costing 150,000 CHF reasonable?].

Peters S, von Moos R, Thurlimann B.

Rev Med Suisse. 2015 Oct 21;11(491):1967-72. German.

PMID:
26672265
31.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ.

Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.

32.

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06).

Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2016 Feb;27(2):324-32. doi: 10.1093/annonc/mdv576. Epub 2015 Dec 8.

33.

Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.

Volk V, Cathomas R, Mark M, von Moos R, Klingbiel D, Brossart P, Mey U.

Support Care Cancer. 2016 May;24(5):2119-2128. doi: 10.1007/s00520-015-3015-z. Epub 2015 Nov 9.

PMID:
26553033
34.

Bone Pain And Bone Targeting Agent (Bta) Treatment Pattern In Patients With Bone Metastases (Bms) From Prostate Cancer (Pc) In Real World Setting In Europe.

Body J, Henry D, von Moos R, Rider A, De Courcy J, Murray G, Bhowmik D, Gatta F, Arellano J, Hechmati G, Qian Y.

Value Health. 2015 Nov;18(7):A493. doi: 10.1016/j.jval.2015.09.1373. Epub 2015 Oct 20. No abstract available.

35.

Bone Pain And Bone Targeting Agent (Bta) Treatment Patterns In Patients With Bone Metastases (Bms) From Breast Cancer (Bc) In Real World Setting In Europe.

von Moos R, Henry D, Body J, Rider A, De Courcy J, Murray G, Bhowmik D, Gatta F, Arellano J, Hechmati G, Qian Y.

Value Health. 2015 Nov;18(7):A493. doi: 10.1016/j.jval.2015.09.1372. Epub 2015 Oct 20. No abstract available.

36.

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Mar;24(3):1327-37. doi: 10.1007/s00520-015-2908-1. Epub 2015 Sep 2.

37.

Health resource utilization associated with skeletal-related events: results from a retrospective European study.

Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R.

Eur J Health Econ. 2016 Jul;17(6):711-21. doi: 10.1007/s10198-015-0716-7. Epub 2015 Aug 8.

38.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A.

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

PMID:
25976743
39.

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu RA, Schacher S, Hess V, Herrmann R.

Ann Oncol. 2015 Apr;26(4):709-14. doi: 10.1093/annonc/mdv011. Epub 2015 Jan 20.

PMID:
25605741
40.

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.

Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, Qian Y.

Support Care Cancer. 2015 Apr;23(4):1157-68. doi: 10.1007/s00520-014-2525-4. Epub 2014 Dec 23. Review.

PMID:
25533578
41.

RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?

Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, Schwitter M.

Oncology. 2015;88(4):257-60. doi: 10.1159/000369975. Epub 2014 Dec 17.

42.

Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.

Brunner S, von Moos R, Mey U, Camenisch Gross U, Freyholdt T, Cathomas R.

Oncol Res Treat. 2014;37(11):646-52. doi: 10.1159/000368313. Epub 2014 Oct 17.

PMID:
25427581
43.

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.

Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.

44.

Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.

Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, Haynes I, Bahl A, von Moos R, Body JJ.

Support Care Cancer. 2015 Jan;23(1):21-8. doi: 10.1007/s00520-014-2309-x. Epub 2014 Jun 18.

45.

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).

Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M.

Lung Cancer. 2014 Aug;85(2):306-13. doi: 10.1016/j.lungcan.2014.04.014. Epub 2014 May 29.

PMID:
24928469
46.

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, Prêtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R.

Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8.

PMID:
24853781
47.

Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice.

Blum D, Koeberle D, Omlin A, Walker J, Von Moos R, Mingrone W, deWolf-Linder S, Hayoz S, Kaasa S, Strasser F, Ribi K.

Support Care Cancer. 2014 Sep;22(9):2425-34. doi: 10.1007/s00520-014-2201-8. Epub 2014 Apr 5.

PMID:
24705855
48.

Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.

Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M.

Ann Oncol. 2014 Aug;25(8):1591-7. doi: 10.1093/annonc/mdu129. Epub 2014 Mar 25.

PMID:
24669017
49.

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).

Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJ, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center.

Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005. Epub 2014 Mar 20.

PMID:
24656636
50.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H.

Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26.

Supplemental Content

Loading ...
Support Center